(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...
This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.
Therapy costs vary widely. In-person therapy in the United States costs an average of $174 per 1-hour session when paid out of pocket, according to a 2023 Milliman report. With commercial health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback